Dependence on J&J MedTech
J&J MedTech accounted for 50% of revenue in 2025, so reduced orders or contract changes would have an outsized impact.
- Scope
- OEM channel and OA Pain Management
- Materiality
- high
Anika Therapeutics, Inc.
Anika Therapeutics, Inc. develops hyaluronic acid-based orthopedic products focused on osteoarthritis pain management and regenerative solutions. The company was founded in 1992 and has built its business around proprietary HA technology used in injection therapies and implantable/regenerative orthopedic applications. In 2024-2025, Anika shifted its strategy to concentrate on its core OA Pain Management and Regenerative Solutions portfolios, including the divestiture of non-core businesses. Its commercial model combines direct selling in the U.S. for selected regenerative products with OEM and distributor partnerships, most notably with J&J MedTech for key OA products. The company serves clinicians, hospitals, ambulatory surgery centers, and distribution partners across the U.S. and international markets.
−5,0 %
56,6 %
−9,6 %
−5,9 %
4.72
3.86
| % | |
|---|---|
| OA Pain Management | 55% Viscosupplementation and related HA-based products used to treat osteoarthritis pain, primarily through office-based injections. |
| Regenerative Solutions | 25% Implantable and biologic orthopedic products designed to support tissue repair and joint preservation in surgical settings. |
| OEM Channel | 20% Products manufactured and supplied to partners such as J&J MedTech, which handle downstream marketing and distribution. |
Anika sells through several distinct customer types, but a small number of large partners account for a substantial...
- OEM partner customersprimary
Large partners such as J&J MedTech buy HA-based OA products for resale and control downstream marketing and distribution.
- Hospitals and ambulatory surgery centersprimary
These facilities buy regenerative and implantable orthopedic products for surgical procedures and inventory availability at point of care.
- Office-based clinicianssecondary
Physicians and clinics buy injection-based OA pain products because they are used in outpatient treatment of osteoarthritis.
- International distributorssecondary
Distributors buy products for local commercialization outside the U.S., supporting geographic expansion and market access.
Anika is headquartered in the United States and manufactures its global commercial supply from a single site in...
- •United States is the core market for OEM supply and direct regenerative sales
- •Bedford, Massachusetts is the single manufacturing site for global commercial supply
- •International revenue is supported by a worldwide distributor network
- •Commercial channel growth has been driven partly by non-U.S. OA Pain Management sales
- •U.S. hospitals and ASCs are key end markets for surgical products
- •Single-site manufacturing increases operational concentration risk
Anika's current strategy is to focus on its OA Pain Management and Regenerative Solutions portfolios after divesting...
01
Portfolio focus on core HA-based orthopedic productsshort-term
Concentrating resources on the highest-value product families should improve execution and reduce distraction from non-core assets.
02
Build direct commercial capability in the U.S.medium-term
Direct control over sales and market access can improve adoption, pricing discipline, and customer relationships for regenerative products.
03
Advance clinical and product development for HA technologymedium-term
Clinical evidence and product innovation are central to differentiation in a competitive orthopedic market.
Anika is exposed to concentration risk because a single customer, J&J MedTech, represented 50% of revenue in 2025, so...
Single manufacturing site disruption
All global commercial supply is manufactured in Bedford, Massachusetts, so any interruption can halt supply and revenue.
- Scope
- Global supply chain
- Materiality
- high
Regulatory delays for Hyalofast and other products
Approval timing affects product launches, market access, and the ability to convert R&D spending into revenue.
- Scope
- Pipeline and international commercialization
- Materiality
- medium
Pricing and reimbursement pressure
Healthcare consolidation and payer pressure can force price concessions or restrict supplier access.
- Scope
- OA Pain Management and hospital channels
- Materiality
- high
Product liability and quality claims
Orthopedic implants and injectable products can generate claims if outcomes, safety, or manufacturing quality are challenged.
- Scope
- Regenerative and OA products
- Materiality
- medium
Revenue recognition across multiple channel models
Can shift revenue between quarters and affect comparability
Inventory reserves
Affects gross profit and operating margin
Goodwill and acquired in-process R&D
Can create non-cash charges that materially affect earnings
Allowance for credit losses and contingencies
Affects operating expenses and reported net income
NIKA PHARMACEUTICALS, INC
NIKA · Pharmaceutical Preparations
OnKure Therapeutics, Inc.
OKUR · Pharmaceutical Preparations
Oruka Therapeutics, Inc.
ORKA · Pharmaceutical Preparations
Kiniksa Pharmaceuticals International, plc
KNSA · Pharmaceutical Preparations
Kiniksa Pharmaceuticals International, plc is a biopharmaceutical company focused on developing and commercializing therapies for diseases with unmet medical…
Aclaris Therapeutics, Inc.
ACRS · Pharmaceutical Preparations
Aclaris Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing small and large molecule therapies for immuno-inflammatory diseases.
DYNATRONICS CORP
DYNTQ · Surgical & Medical Instruments & Apparatus
Dynatronics Corp designs, manufactures, and sells restorative medical products used in physical therapy, rehabilitation, orthopedics, pain management, and athletic training.
: 11/08/2026